| |
|
Form Serial Number: |
DB20220107E00451 |
| 1.
Date of relevant event: |
30/08/2021
(dd/mm/yyyy)
|
| 2.
Date when director became aware of the relevant event / interest in the shares (if later): |
04/01/2022
(dd/mm/yyyy)
|
| 3.
Stock code: |
02359 |
| 4.
Name of listed corporation: |
WuXi AppTec Co., Ltd. - A Shares |
|
5.
Name of associated corporation of listed corporation: |
Shanghai SynTheAll Pharmaceutical Co., Ltd. (上海合全藥業股份有限公司) |
|
6.
Registered office: |
上海化學工業區金山分區（西部）月工路9號 |
|
7.
Principal place of business: |
上海化學工業區金山分區（西部）月工路9號 |
|
8.
Class of shares in which interested: |
Ordinary shares |
|
9.
Number of issued shares in class: |
531,338,441 |
| 12.
Exchange on which listed: |
|
| 13.
Name of director (English) as printed on HKID Card/Passport: |
| (Surname) |
Chen |
| (Other names) |
Minzhang |
|
|
|
| 16.
Name of director (Chinese): |
陳民章 |
| 17.
Chinese Character Code as printed on HKID Card: |
|
|
| 30.
Details of relevant event: |
| |
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Nature of consideration
|
| Long position |
| 1705 | Miscellaneous
Notice filed because you became a director or chief executive of the listed corporation |
|
|
|
|
|
|
|
|
|
| Short position |
|
|
|
|
|
|
|
|
|
|
|
| |
| 31.
Total shares immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 53,220 | 0.01 |
|
| |
| 32.
Total shares immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 53,220 | 0.01 |
|
| |
| 33.
Capacity in which interests disclosed in Box 32 are held: |
| Capacity code | Number of shares |
| |
|
| |
| 34.
Further information in derivative interests in associated corporation: |
| Derivatives code |
Exercise period (dd/mm/yyyy) |
Consideration - if derivatives granted by associated corporation |
Number of shares |
| | | Begins | Ends | Currency | Price for grant | Currency | Exercise price | Currency | Price on assignment | |
| | | | | | | | | | | |
|
| |
| 35.
Further information in relation to interests of children under 18 and/or spouse: |
| Child/Spouse | Name of child/spouse | Number of shares |
| | |
|
| |
| 36.
Further information in relation to interests of corporations controlled by director: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| | | | | |
|
| |
| 37.
Further information in relation to interests held by director jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| | |
|
| |
| 38.
Further information from a trustee, a beneficiary of a trust, or a person who has set up a discretionary trust: |
| Names of Trust | Address | Status code | Number of shares |
| | | |
|
| |
| 39.
Supplementary information: |
Dr. Minzhang Chen was appointed as an additional co-chief executive officer of WuXi AppTec Co., Ltd. (無錫藥明康德新藥開發股份有限公司) (the "Company") with effect from August 30, 2021. For further details, please refer to the announcement of the Company dated August 2, 2021.
|
| 40.
Log/Serial Number of the previous form: |
|
|
Date of filing this Form 3B: |
07/01/2022
(dd/mm/yyyy)
|
|